118 related articles for article (PubMed ID: 37922573)
1. Identification of UBFD1 as a prognostic biomarker and molecular target among estrogen receptor-positive breast cancer.
Duan L; Liu R; Cui X; Zhang Q; Cao D; Chen M; Zhang A
Biochem Biophys Res Commun; 2023 Dec; 686():149171. PubMed ID: 37922573
[TBL] [Abstract][Full Text] [Related]
2. NUDT5 as a novel drug target and prognostic biomarker for ER-positive breast cancer.
Tong XY; Quan Y; Zhang HY
Drug Discov Today; 2021 Mar; 26(3):620-625. PubMed ID: 33276127
[TBL] [Abstract][Full Text] [Related]
3. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
Wang Y; Gong X; Zhang Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
[TBL] [Abstract][Full Text] [Related]
4. The prognostic implications and tumor-suppressive functions of CYR61 in estrogen receptor-positive breast cancer.
Zhang C; Li Z; Hu K; Ren Y; Zhang H; Zhao Y; Wei W; Tu S; Yan X
Front Immunol; 2023; 14():1308807. PubMed ID: 38259466
[TBL] [Abstract][Full Text] [Related]
5. An estrogen receptor (ER)-related signature in predicting prognosis of ER-positive breast cancer following endocrine treatment.
Tang J; Cui Q; Zhang D; Liao X; Zhu J; Wu G
J Cell Mol Med; 2019 Aug; 23(8):4980-4990. PubMed ID: 31124293
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.
Ma CX; Bose R; Ellis MJ
Adv Exp Med Biol; 2016; 882():125-54. PubMed ID: 26987533
[TBL] [Abstract][Full Text] [Related]
7. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.
Tomiguchi M; Yamamoto Y; Yamamoto-Ibusuki M; Goto-Yamaguchi L; Fujiki Y; Fujiwara S; Sueta A; Hayashi M; Takeshita T; Inao T; Iwase H
Cancer Sci; 2016 Apr; 107(4):491-8. PubMed ID: 26801869
[TBL] [Abstract][Full Text] [Related]
9. Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.
Xia S; Lin Q
Technol Cancer Res Treat; 2022; 21():15330338221090351. PubMed ID: 35450488
[TBL] [Abstract][Full Text] [Related]
10. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
[TBL] [Abstract][Full Text] [Related]
11. GPI: An indicator for immune infiltrates and prognosis of human breast cancer from a comprehensive analysis.
Zeng J; Yi J; Tan S; Zeng Y; Zou L; Zhang C; Liu L; Yi P; Fan P; Yu J
Front Endocrinol (Lausanne); 2022; 13():995972. PubMed ID: 36246907
[TBL] [Abstract][Full Text] [Related]
12. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529
[TBL] [Abstract][Full Text] [Related]
13. Tumor characteristics and prognosis in familial breast cancer.
Arpino G; Pensabene M; Condello C; Ruocco R; Cerillo I; Lauria R; Forestieri V; Giuliano M; De Angelis C; Montella M; Crispo A; De Placido S
BMC Cancer; 2016 Nov; 16(1):924. PubMed ID: 27899083
[TBL] [Abstract][Full Text] [Related]
14. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer.
McGovern SL; Qi Y; Pusztai L; Symmans WF; Buchholz TA
Breast Cancer Res; 2012 May; 14(3):R72. PubMed ID: 22559056
[TBL] [Abstract][Full Text] [Related]
15. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
16. Methylome and transcriptome analyses reveal insights into the epigenetic basis for the good survival of hypomethylated ER-positive breast cancer subtype.
Chen XQ; Zhang F; Su QC; Zeng C; Xiao FH; Peng Y
Clin Epigenetics; 2020 Jan; 12(1):16. PubMed ID: 31959227
[TBL] [Abstract][Full Text] [Related]
17. The expression of insulin receptor substrate 1 and estrogen receptor as prognostic factor on breast cancer patient.
Kim HG; Woo SU; Kim HY; Son GS; Lee JB; Bae JW; Woo OH; Yang DS; Seo JH; Kim AR
J Cancer Res Ther; 2018 Jun; 14(Supplement):S494-S498. PubMed ID: 29970713
[TBL] [Abstract][Full Text] [Related]
18. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype.
Hefti MM; Hu R; Knoblauch NW; Collins LC; Haibe-Kains B; Tamimi RM; Beck AH
Breast Cancer Res; 2013; 15(4):R68. PubMed ID: 23971947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]